Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

@article{Chapuis2010DualIO,
  title={Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.},
  author={Nicolas Chapuis and J{\'e}r{\^o}me Tamburini and Alexa S. Green and Christine Vignon and Val{\'e}rie Bardet and Aymeric Neyret and Melanie Pannetier and Lise Willems and Sophie Elizabeth Park and Alexandre Macone and S Maira and Norbert Ifrah and François J Dreyfus and Olivier H{\'e}rault and Catherine Lacombe and Patrick Mayeux and Didier Bouscary},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 22},
  pages={5424-35}
}
PURPOSE The growth and survival of acute myeloid leukemia (AML) cells are enhanced by the deregulation of signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR). Major efforts have thus been made to develop molecules targeting these activated pathways. The mTOR serine/threonine kinase belongs to two separate complexes: mTORC1 and mTORC2. The mTORC1 pathway is rapamycin sensitive and controls protein translation through the phosphorylation of 4E… CONTINUE READING